Cancer Biomarker Market Size
In 2022, the Global Cancer Biomarker Market was valued at USD 13.2 billion and is anticipated to experience significant growth, reaching an estimated USD 32.5 billion by 2031. The market is projected to grow at a CAGR of 12.3% during the forecast period from 2024 to 2031.
The market is currently in a transformational phase, driven by several major trends such as the emergence of liquid biopsy, the use of genomic biomarkers, immuno-oncology biomarkers, and the integration of artificial intelligence (AI).
Moreover, factors such as the increasing prevalence of cancer, a shift towards personalized medicine, advancements in biomarker technology, a growing focus on early detection, and the rising adoption of targeted therapies are driving the growth of the cancer biomarker market. Owing to technological advancements in these areas, the market is witnessing increased demand from North American regions. Key players in the market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., among others.
-
Sarcoma
-
Colorectal Cancer
-
Cervical Cancer
-
Lung Cancer
-
Breast Cancer
-
PSA
-
HER-2
-
EGFR
-
KRAS
-
Others
-
OMICS Technologies
-
Cytogenetics
-
Immunoassays
-
Imaging Technologies
-
Bioinformatics
Major players are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Enzo Biochem, Inc., Merck Millipore and Micron Technology.
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian